SG11202108398YA - Anti-claudin 18 antibodies and methods of use thereof - Google Patents

Anti-claudin 18 antibodies and methods of use thereof

Info

Publication number
SG11202108398YA
SG11202108398YA SG11202108398YA SG11202108398YA SG11202108398YA SG 11202108398Y A SG11202108398Y A SG 11202108398YA SG 11202108398Y A SG11202108398Y A SG 11202108398YA SG 11202108398Y A SG11202108398Y A SG 11202108398YA SG 11202108398Y A SG11202108398Y A SG 11202108398YA
Authority
SG
Singapore
Prior art keywords
claudin
antibodies
methods
Prior art date
Application number
SG11202108398YA
Inventor
Han Li
Ming Lei
Yi Pei
Haichun Huang
Original Assignee
Novarock Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novarock Biotherapeutics Ltd filed Critical Novarock Biotherapeutics Ltd
Publication of SG11202108398YA publication Critical patent/SG11202108398YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202108398YA 2019-02-01 2020-02-03 Anti-claudin 18 antibodies and methods of use thereof SG11202108398YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800359P 2019-02-01 2019-02-01
US201962891925P 2019-08-26 2019-08-26
PCT/US2020/016459 WO2020160560A2 (en) 2019-02-01 2020-02-03 Anti-claudin 18 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202108398YA true SG11202108398YA (en) 2021-08-30

Family

ID=71842386

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108398YA SG11202108398YA (en) 2019-02-01 2020-02-03 Anti-claudin 18 antibodies and methods of use thereof

Country Status (9)

Country Link
US (3) US11407828B2 (en)
EP (1) EP3917564A4 (en)
JP (1) JP2022519118A (en)
KR (1) KR20210134321A (en)
CN (1) CN113645996B (en)
AU (1) AU2020217012A1 (en)
CA (1) CA3128502A1 (en)
SG (1) SG11202108398YA (en)
WO (1) WO2020160560A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11643455B2 (en) 2018-04-13 2023-05-09 Albert Einstein College Of Medicine High-affinity Mycobacterium tuberculosis capsule-specific human monoclonal antibody
MX2021007939A (en) * 2018-12-28 2021-10-22 Nanjing Genscript Biotech Co Ltd Claudin18.2 binding moieties and uses thereof.
KR20210134321A (en) * 2019-02-01 2021-11-09 노바록 바이오테라퓨틱스 리미티드 Anti-claudin 18 antibodies and methods of use thereof
JP2023545382A (en) * 2020-09-30 2023-10-30 江蘇恒瑞医薬股▲ふん▼有限公司 Pharmaceutical compositions containing antibody-drug conjugates and uses thereof
WO2022111616A1 (en) * 2020-11-30 2022-06-02 石药集团巨石生物制药有限公司 Anti-cldn18.2 antibody, drug conjugate, and preparation method therefor and use thereof
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
EP4263598A4 (en) * 2020-12-15 2025-04-09 Albert Einstein College of Medicine HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE CAPSULE OF MYCOBACTERIUM TUBERCULOSIS
JP2024502907A (en) * 2020-12-22 2024-01-23 ベルティス インコーポレイテッド Pancreatic ductal adenocarcinoma subtype determination method and subtype determination kit
PE20231561A1 (en) 2020-12-23 2023-10-03 Sotio Biotech A S ANTIBODY-DRUG CONJUGATES SPECIFIC FOR TUMORS WITH CLAUDIN 18.2
EP4299593A4 (en) * 2021-04-02 2025-12-10 Oricell Therapeutics Co Ltd CLDN18.2-ANTIGEN-BINDING PROTEIN AND USE OF IT
AU2022284146B2 (en) * 2021-05-31 2026-01-08 Shijiazhuang Yiling Pharmaceutical Co., Ltd. Monoclonal antibodies against cldn18.2 and fc-engineered versions thereof
CA3236417A1 (en) 2021-11-05 2023-05-11 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal antibodies against carcinoembryonic antigens, and their uses
AU2023278315A1 (en) * 2022-05-31 2024-12-12 CSPC Megalith Biopharmaceutical Co., Ltd. Pharmaceutical composition of recombinant anti-human cldn18.2 monoclonal antibody-mmae conjugate
CN117777288A (en) * 2022-09-29 2024-03-29 南京博望医药科技有限公司 Anti-claudin 18.2 antibody
TW202434307A (en) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 Antibody conjugated drugs and their uses
WO2024211459A1 (en) * 2023-04-04 2024-10-10 Zai Lab (Shanghai) Co., Ltd Use of anti-claudin antibody for cancer treatment based on certain biomarkers
CN118530349B (en) * 2024-06-03 2025-04-11 华中农业大学 A monoclonal antibody that can neutralize different serotypes of porcine rotavirus

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2434961T5 (en) 1998-04-20 2018-01-18 Roche Glycart Ag Antibody glycosylation engineering to improve antibody-dependent cell cytotoxicity
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
GB0306137D0 (en) 2003-03-18 2003-04-23 Qinetiq Ltd Fibre laser
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
CA2618681C (en) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
DK1979001T3 (en) * 2005-12-13 2012-07-16 Medimmune Ltd BINDING PROTEINS SPECIFIC TO INSULIN-LIKE GROWTH FACTORS AND APPLICATIONS THEREOF
US20070214515A1 (en) * 2006-03-09 2007-09-13 E.I.Du Pont De Nemours And Company Polynucleotide encoding a maize herbicide resistance gene and methods for use
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
EP2641919A3 (en) * 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
MX2010008688A (en) 2008-02-07 2010-08-30 Schering Corp Engineered anti-tslpr antibodies.
US8871207B2 (en) * 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
ES2662519T3 (en) * 2008-07-25 2018-04-06 Institute For Research In Biomedicine Neutralizing antibodies against influenza A virus and uses of these
UA109633C2 (en) * 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
WO2011086001A1 (en) * 2010-01-15 2011-07-21 Cormus Srl Antibodies for the treatment of hcv
EP2542577A1 (en) 2010-03-01 2013-01-09 Lostam Biopharmaceuticals Ltd Improved therapeutic antibodies against flagellated pseudomonas aeruginosa
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
ES2863626T3 (en) * 2010-10-27 2021-10-11 Amgen Inc DKK1 antibodies and methods of use
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
US9371383B2 (en) * 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
JO3462B1 (en) * 2012-08-22 2020-07-05 Regeneron Pharma Human Antibodies to GFR?3 and methods of use thereof
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
WO2014204941A1 (en) * 2013-06-17 2014-12-24 The Johns Hopkins University Antibodies to human resistin
KR20170063946A (en) * 2014-10-08 2017-06-08 에프. 호프만-라 로슈 아게 Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
AR103268A1 (en) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co ANTIBODIES AGAINST TIGIT
JP2018507254A (en) * 2015-02-02 2018-03-15 アイツー ファーマシューティカルズ， インコーポレーテッド Anti-alternative light chain antibody
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
CA2999747A1 (en) * 2015-09-04 2017-03-09 Remd Biotherapeutics, Inc. Methods for treating heart failure using glucagon receptor antagonistic antibodies
KR20180068990A (en) * 2015-10-01 2018-06-22 포텐자 테라퓨틱스, 인코포레이티드 Anti-TIGIT antibody-binding proteins and methods for their use
WO2017055395A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
CN108738324B (en) * 2015-11-19 2022-06-21 百时美施贵宝公司 Anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and uses thereof
TW201734049A (en) * 2016-01-22 2017-10-01 健生生物科技公司 Anti-ROR1 antibodies, ROR1 X CD3 bispecific antibodies, and methods of using the same
TWI781934B (en) 2016-05-27 2022-11-01 美商艾吉納斯公司 Anti-tim-3 antibodies and methods of use thereof
ES2979068T3 (en) * 2016-07-08 2024-09-24 Crage Medical Co Ltd Antibodies to anti-claudin 18A2 and their use
US10626169B2 (en) * 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
US11312769B2 (en) * 2017-03-22 2022-04-26 Bluefin Biomedicine, Inc. Anti-TMEFF1 antibodies and antibody drug conjugates
AU2018254566B2 (en) * 2017-04-21 2025-02-13 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
CA3089653A1 (en) 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
TW202003562A (en) 2018-03-14 2020-01-16 中國大陸商北京軒義醫藥科技有限公司 Anti-claudin 18.2 (CLDN18.2) antibodies
SG11202007074PA (en) 2018-05-18 2020-08-28 Lanova Medicines Ltd Company Anti-claudin 18.2 antibodies and uses thereof
CN111867630B (en) 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 Antibodies, bispecific antibodies, ADCs and CARs targeting CLDN18.2 and their applications
US11505618B2 (en) 2018-07-18 2022-11-22 Askgene Pharma Inc. Antibodies and methods for making and using the same
IL280467B2 (en) 2018-08-03 2025-03-01 Amgen Res Munich Gmbh Antibody constructs for cldn18.2 and cd3
CN110857322A (en) 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 Anti-human claudin18.2 monoclonal antibody and application thereof
EP3878863A4 (en) 2018-08-27 2022-06-22 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-claudin18.2 antibody and use thereof
JP7401538B2 (en) 2018-10-22 2023-12-19 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Anti-CLDN18.2 antibody and its use
SG11202105885WA (en) 2018-12-07 2021-07-29 Zlip Holding Ltd Anti-claudin antibodies and uses thereof
JP7520848B2 (en) 2018-12-28 2024-07-23 スパークス・セラピューティクス・インコーポレイテッド Claudin 18.2-specific binding molecules, compositions and methods thereof for the treatment of cancer and other diseases
WO2020135201A1 (en) 2018-12-28 2020-07-02 四川科伦博泰生物医药股份有限公司 Antibody and use thereof
CN109762067B (en) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 Antibodies that bind human Claudin18.2 and uses thereof
KR20210134321A (en) * 2019-02-01 2021-11-09 노바록 바이오테라퓨틱스 리미티드 Anti-claudin 18 antibodies and methods of use thereof
SG11202109052YA (en) 2019-03-29 2021-10-28 Phanes Therapeutics Inc Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
MY208022A (en) 2019-04-01 2025-04-08 Shanghai hengrui pharmaceutical co ltd Anti-claudin 18.2 antibody and application thereof
EP3960766A4 (en) 2019-04-19 2022-12-07 Keymed Biosciences Co.,Ltd. TUMOR THERAPY AND USE THEREOF
CN111944048B (en) 2019-05-16 2023-10-03 启愈生物技术(上海)有限公司 Anti-CLDN antibodies and pharmaceutical compositions and detection methods thereof
WO2020239005A1 (en) 2019-05-30 2020-12-03 山东博安生物技术有限公司 Antibody or chimeric antigen receptor which targets claudin 18.2
US20220235129A1 (en) 2019-07-12 2022-07-28 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Cldn18.2 antibody and use thereof
JP2022541435A (en) 2019-07-17 2022-09-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Claudin-18 antibodies and methods of treating cancer
KR20220045040A (en) * 2019-08-20 2022-04-12 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 Novel anti-CLDN18.2 antibody

Also Published As

Publication number Publication date
CA3128502A1 (en) 2020-08-06
KR20210134321A (en) 2021-11-09
WO2020160560A2 (en) 2020-08-06
US20220041712A1 (en) 2022-02-10
WO2020160560A3 (en) 2020-09-17
CN113645996B (en) 2024-04-02
AU2020217012A1 (en) 2021-08-19
JP2022519118A (en) 2022-03-18
US11407828B2 (en) 2022-08-09
US20230067757A1 (en) 2023-03-02
US20230272063A1 (en) 2023-08-31
EP3917564A2 (en) 2021-12-08
EP3917564A4 (en) 2022-12-21
CN113645996A (en) 2021-11-12

Similar Documents

Publication Publication Date Title
SG11202108398YA (en) Anti-claudin 18 antibodies and methods of use thereof
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
SG11202110145SA (en) Antibodies against sars-cov-2 and methods of using the same
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
ZA202300348B (en) Anti-sortilin antibodies and methods of use thereof
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
IL287282A (en) Anti-mertk antibodies and their methods of use
IL290741A (en) Anti-cd96 antibodies and methods of use thereof
IL289952A (en) Anti-ms4a4a antibodies and methods of use thereof
IL277212A (en) Anti-klk5 antibodies and methods of use
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof
IL291461A (en) Anti-alpha-synuclein antibodies and methods of use thereof
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL288886A (en) Antibodies and methods of use
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
ZA202201160B (en) Anti-grp78 antibodies and method of use thereof
IL284069B2 (en) Anti-angptl3/8 complex antibodies and methods of using the same
HK40064823A (en) Anti-claudin 18 antibodies and methods of use thereof
HK40037554A (en) Anti-lrp5/6 antibodies and methods of use
HK40054782A (en) Anti-il-36 antibodies and methods of use thereof
HK40064767A (en) Anti-clec2d antibodies and methods of use thereof
HK40057218A (en) Anti-lilrb2 antibodies and methods of use thereof